Information Provided By: 
Fly News Breaks for March 31, 2015
RARE
Mar 31, 2015 | 08:30 EDT
As previously reported, Ultragenyx was added to the Focus List at Baird. The firm cited several trials programs that make the company one of the most catalyst rich names on its list, if not all of biotech. Baird remains confident in the execution side of the story and reiterated its Outperform rating and $75 price target on Ultragenyx shares.
News For RARE From the Last 2 Days
